DXB 0.00% 45.5¢ dimerix limited

DXB Chart, page-849

  1. 4,200 Posts.
    lightbulb Created with Sketch. 786
    I can't believe people invest in a stock without doing any research!

    Dimerix is not a developer of new drugs. Their "product" is a discovery platform that identifies combinations of two existing drugs that can work in synergy to treat a particular medical condition better than each individual drug on its own. The first of these (DMX-200) is currently undergoing trials for kidney disease, and is a combination of two existing off-patent drugs (irbesartan and propagermanium) that have each been around for decades.

    The next candidate will be DMX-700 for treatment of pulmonary heart disease. There are more candidates in the pipeline.
    Hopefully DMX-200 will be approved so the revenue it generates can fund the development of this pipeline (and pay a healthy dividend to shareholders).

    https://dimerix.com/technology/
    Last edited by dyeman: 18/05/24
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
45.5¢
Change
0.000(0.00%)
Mkt cap ! $250.5M
Open High Low Value Volume
46.5¢ 47.5¢ 45.5¢ $934.4K 2.015M

Buyers (Bids)

No. Vol. Price($)
14 548864 45.0¢
 

Sellers (Offers)

Price($) Vol. No.
46.0¢ 35747 5
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.